Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...
With FibroSIGHT, we aim to empower clinicians with a more definitive and accurate assessment of liver fibrosis." MASH has long been a challenging and progressive liver disease, characterized by ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...
Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...
News-Medical.Net on MSN13d
Study reveals the role of transcription factors as therapeutic gateways in MAFLDMetabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...
PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback